

## Alchemia Announces Fondaparinux Profit Share for Second Quarter FY2015

**BRISBANE, Australia: 19 February 2015** – Alchemia Limited, (ASX: ACL) a drug discovery and development company, today reported gross revenue of \$1.91m (US\$1.55m) from its profit share on US sales of its generic anti-coagulant drug fondaparinux for the quarter ending 31 December 2014.

Alchemia will receive \$1.29m (US\$1.05m) as net revenue for the quarter, after deducting \$0.62m (US\$0.50m) for Alchemia's contribution to yield and cost of goods improvement activities. This payment represents the final instalment of Alchemia's contribution to these activities. Therefore, in all future quarters, there will be no further deductions to the gross revenue for process improvements.

The overall fondaparinux market continued to experience both volume and pricing pressure during the quarter. Dr Reddy's volume market share in the US improved from 33% to 37% in this quarter (Dr Reddy's recorded a volume growth of 8% compared to the previous quarter), whereas overall Fondaparinux volume decreased by 3% in the same quarter (Source: IMS)

As previously announced, fondaparinux was launched in Canada and India in 2014, however it is in early stages of market launch and is yet to reach profitability. Consequently, Alchemia has not received any profit share from sales in Canada or India to date.

### About Alchemia Limited

Alchemia is a drug discovery and development company marketing fondaparinux, an FDA approved, injectable antithrombotic, in the US and other markets, via partner Dr. Reddy's Laboratories. In October 2014, Alchemia announced that its Phase III trial of HA-Irinotecan in Metastatic Colorectal Cancer did not meet its primary endpoint of statistically significant improvement in progression-free survival. HA-Irinotecan is the lead product in Alchemia's oncology pipeline based on its proprietary HyACT drug delivery platform, which targets anti-cancer drugs to solid tumours. The company is actively seeking a corporate transaction or partnership for the HyACT platform to support further potential clinical development of HA-Irinotecan and follow-on drug candidates. Alchemia also has a proprietary small molecule drug discovery platform VAST, based on the Company's deep chemistry expertise. The VAST technology is being utilised in collaborations with leading academic institutions and is partnered with AstraZeneca AB. Alchemia has engaged Evolution Life Science Partners to execute a corporate transaction for the VAST technology, as part of the ongoing strategic review and business assessment.

### Contacts

[www.alchemia.com.au](http://www.alchemia.com.au)

#### Alchemia Limited

Tracie Ramsdale  
Executive Director  
Alchemia Limited  
Tel: +61 7 3340 0200

#### Investor Relations USA

Candice Knoll  
Blueprint Life Science Group  
+1 415 375 3340 Ext. 105  
[cknoll@bplifescience.com](mailto:cknoll@bplifescience.com)